Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.12 USD
-0.04 (-1.27%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $3.11 -0.01 (-0.32%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABUS 3.12 -0.04(-1.27%)
Will ABUS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABUS
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up
Other News for ABUS
Analysts Have Conflicting Sentiments on These Healthcare Companies: Halozyme (HALO), Arbutus Biopharma (ABUS) and Annexon Biosciences (ANNX)
Arbutus Reports Promising Hepatitis B Trial Results
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300